Growing evidence, however, suggests a role for conservative, expectant management in patients with low-risk (Ta and low-grade) superficial bladder tumors, which could reduce the burden of surgical ...

At present, the clinical behavior of T1 tumors cannot be prospectively predicted. Various options are available for the management of superficial bladder cancers, such as transurethral resection ...

The high recurrence rate and the unpredictability of the progression pattern of bladder cancer have led to the widespread use of intravesical therapy as a supplement to TUR. Superficial bladder ...

BCG is also used as a biotherapy for superficial bladder carcinoma. Despite being the most successful cancer biotherapy, the mechanism of action and determinants of response to BCG remain obscure. We ...

Bladder cancer occurs when cells in the bladder — a water balloon–like organ in the lower abdomen that stores urine — grow out of control. There are many treatment options for bladder cancer ...

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

Bladder cancer group is co-led by urologist, PhD, Jukka Sairanen (invasive bladder cancer) and urologist, PhD, Riikka Järvinen (superficial bladder cancer). The group has several retrospective and ...

Bladder cancer remains one of the most common cancers in the United States and is a cause of substantial morbidity and mortality. The treatment of choice for superficial (non muscle-invasive) bladder ...